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Abstract  
For years, the natural diversity intrinsic to the mammalian immune system has been 
harnessed for the generation of specific macromolecular recognition tools. With the 
development of in vitro selection techniques, the ability to create tailor-made, high 
affinity peptide-based reagents has become more powerful. The directed evolution of 
peptides and proteins has many applications in proteomics and functional genomics 
research. Combinatorial peptide libraries based on stable protein scaffolds with diversity 
contained within defined regions of the domain’s surface enable the evolution of novel 
molecules. One scaffold utilized for in vitro selection experiments is the 10th fibronectin 
type III domain of human fibronectin. This domain is similar to the immunoglobulin fold, 
although it does not contain disulfides and therefore may be more appropriate for 
intracellular expression. We have created a new combinatorial library based on this 
domain and have determined that it is able to tolerate diversity within two loops. Our 
structured fibronectin library was used for selecting novel, high-affinity reagents by 
mRNA display. We applied this library towards two important systems, the NF-κB 
pathway and the SARS coronavirus. In both experiments, we generated high-affinity 
binders which were functional both in vitro and in vivo. A modification-specific, 
phospho-IκBα-binding fibronectin was selected with an affinity of 18 nM. The phospho-
IκBα binder was over 1000-fold specific for the phosphorylated state and was able to 
inhibit IκBα degradation in vivo. High-affinity SARS nucleocapsid-binding fibronectins 
were also selected which were able to inhibit virus replication by over 1000-fold when 
expressed in SARS infected cells. Both selections demonstrate the utility of the 
fibronectin library for generating novel protein affinity reagents.  
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